Medpace Holdings, Inc. MEDP
We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. 10-K, Item 1
- Employees
- 6,200
- Headquarters
- Cincinnati, OH
- CEO
- August J. Troendle
- Next results
- around Feb 8, 2027
MEDP among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
4 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 10, 2026 against Feb 11, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
10 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 9 checks found nothing to note
-
Receivables growing faster than revenueReceivables +35.6% ($296.4M to $402.1M) vs revenue +20.0% ($2.1B to $2.5B), +15.7 pts apart
-
Cash from operations $713.2M vs net income $451.1M (FY ending Dec 31, 2025)
8 more checks with nothing to note
-
Same auditor in both 10-Ks: Deloitte & Touche LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Revenue Recognition - Clinical Research
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
4 paragraphs in Risk Factors that were not in the 10-K filed Feb 11, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
•tariffs imposed by the U.S. government on certain imported goods, equipment, technology, or supplies used in our clinical trials, any retaliatory and/or reciprocal tariffs imposed on U.S. exports by foreign countries, including China, as well as any additional tariffs, duties, or other trade measures or restrictions could increase our…
-
Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
applied and enforced. The materialization of any such risks could have an adverse impact on our financial condition, results of operations, cash flows and reputation.
-
Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
fines or penalties. In addition, negative publicity regarding regulatory compliance of our customers’ clinical trials, programs or products could have an adverse effect on our business and reputation.
-
Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
liable for claims with respect to the actions of third party investigators and the institutions at which clinical trials may be conducted.
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $1.5B | $1.9B | $2.1B | $2.5B |
| Net income | $245.4M | $282.8M | $404.4M | $451.1M |
| Operating cash flow | $388.1M | $433.4M | $608.8M | $713.2M |
| Free cash flow | $351.2M | $396.7M | $572.3M | $681.9M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$2.5B ▲ 20.0% in FY2025$451.1M ▲ 11.6% in FY2025$681.9M ▲ 19.2% in FY2025
Recent filings
8 filings in the last 30 days · SEC EDGAR
-
Planned saleOct 29, 2026EWALD STEPHEN P (Officer) gave notice of a planned sale of 1,245 shares worth about $859K Form 144, approximate sale date Oct 29, 2026
-
Planned saleOct 27, 2026BURWIG SUSAN E (Officer) gave notice of a planned sale of 3,940 shares worth about $2.7M Form 144, approximate sale date Oct 27, 2026
-
Planned saleOct 26, 2026BURWIG SUSAN E (Officer) gave notice of a planned sale of 16,060 shares worth about $10.9M Form 144, approximate sale date Oct 26, 2026
-
Planned saleOct 22, 2026August J. Troendle (Chief Executive Officer, President and Chairman of the Board) adopted a trading arrangement reported in the 10-Q, up to 307,959 shares
-
Planned saleOct 22, 2026Susan E. Burwig (Executive Vice President, Operations) adopted a trading arrangement reported in the 10-Q, up to 7,500 shares
About the company
Medpace Holdings, Inc., Cincinnati, OH · from the 10-K filed Feb 10, 2026
We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics. We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our therapeutic expertise. We believe this combination results in timely and cost-effective delivery of clinical development services for our customers.
- Headquarters
- Cincinnati, OH
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Oct 21, 2026
- Incorporated in
- DE
Employees, at the top of the page: "As of December 31, 2025 we had approximately 6,200 employees located across 46 countries" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 10, 2026 (open at SEC), compared with the 10-K filed Feb 11, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MEDP/export.csv") into a cell.